There are no differences in the outcome of coronary perforations occurring during bivalirudin anticoagulation compared to those occurring during heparin anticoagulation




Background


When bivalirudin (BIV) is used as an intraprocedural anticoagulant for PCI in lieu of heparin (HEP), the risk of post-PCI bleeding appears to be smaller. This benefit may be a result of its shorter half life. Unlike HEP, its effects cannot be reversed, a potential problem when coronary perforation (PERF) occurs. This study was undertaken to assess that possibility.

Only gold members can continue reading. Log In or Register to continue

Related posts:

  1. Understanding the impact of drug-eluting stent on vascular function and the nitric oxide pathway genes using a pig coronary artery stent implantation model
  2. Statin improves outcome of patients presenting with first acute myocardial infarction
  3. Definite stent thrombosis: a 2-center New Zealand registry
  4. Using online adjudication to optimize CV endpoint assessment process

Stay updated, free articles. Join our Telegram channel
Tags:
Nov 16, 2017 | Posted by in CARDIOLOGY | Comments Off on There are no differences in the outcome of coronary perforations occurring during bivalirudin anticoagulation compared to those occurring during heparin anticoagulation

Full access? Get Clinical Tree
Get Clinical Tree app for offline access